These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 31369629)

  • 41. Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction.
    Kang SW; Jeon S; Yoo HS; Chung SJ; Lee PH; Sohn YH; Yun M; Evans AC; Ye BS
    Neurology; 2019 Apr; 92(17):e2015-e2026. PubMed ID: 30944239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroimaging markers of global cognition in early Alzheimer's disease: A magnetic resonance imaging-electroencephalography study.
    Waser M; Benke T; Dal-Bianco P; Garn H; Mosbacher JA; Ransmayr G; Schmidt R; Seiler S; Sorensen HBD; Jennum PJ
    Brain Behav; 2019 Jan; 9(1):e01197. PubMed ID: 30592179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuro-degeneration profile of Alzheimer's patients: A brain morphometry study.
    Ramos Bernardes da Silva Filho S; Oliveira Barbosa JH; Rondinoni C; Dos Santos AC; Garrido Salmon CE; da Costa Lima NK; Ferriolli E; Moriguti JC
    Neuroimage Clin; 2017; 15():15-24. PubMed ID: 28459000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brain age and Alzheimer's-like atrophy are domain-specific predictors of cognitive impairment in Parkinson's disease.
    Charissé D; Erus G; Pomponio R; Gorges M; Schmidt N; Schneider C; Liepelt-Scarfone I; Riedel O; Reetz K; Schulz JB; Berg D; Storch A; Witt K; Dodel R; Kalbe E; Kassubek J; Hilker-Roggendorf R; Baudrexel S
    Neurobiol Aging; 2022 Jan; 109():31-42. PubMed ID: 34649002
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Divergent magnetic resonance imaging atrophy patterns in Alzheimer's disease and primary age-related tauopathy.
    Quintas-Neves M; Teylan MA; Morais-Ribeiro R; Almeida F; Mock CN; Kukull WA; Crary JF; Oliveira TG
    Neurobiol Aging; 2022 Sep; 117():1-11. PubMed ID: 35640459
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cerebral changes improved by physical activity during cognitive decline: A systematic review on MRI studies.
    Haeger A; Costa AS; Schulz JB; Reetz K
    Neuroimage Clin; 2019; 23():101933. PubMed ID: 31491837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced detection of cortical atrophy in Alzheimer's disease using structural MRI with anatomically constrained longitudinal registration.
    Iannopollo E; Garcia K;
    Hum Brain Mapp; 2021 Aug; 42(11):3576-3592. PubMed ID: 33988265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
    Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
    Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Classification of Alzheimer's disease and prediction of mild cognitive impairment-to-Alzheimer's conversion from structural magnetic resource imaging using feature ranking and a genetic algorithm.
    Beheshti I; Demirel H; Matsuda H;
    Comput Biol Med; 2017 Apr; 83():109-119. PubMed ID: 28260614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of change in FreeSurfer version on classification accuracy of patients with Alzheimer's disease and mild cognitive impairment.
    Chepkoech JL; Walhovd KB; Grydeland H; Fjell AM;
    Hum Brain Mapp; 2016 May; 37(5):1831-41. PubMed ID: 27018380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Löwe LC; Gaser C; Franke K;
    PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia.
    Du AT; Schuff N; Kramer JH; Rosen HJ; Gorno-Tempini ML; Rankin K; Miller BL; Weiner MW
    Brain; 2007 Apr; 130(Pt 4):1159-66. PubMed ID: 17353226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and demographic predictors of mild cognitive impairment for converting to Alzheimer's disease and reverting to normal cognition.
    Tokuchi R; Hishikawa N; Kurata T; Sato K; Kono S; Yamashita T; Deguchi K; Abe K
    J Neurol Sci; 2014 Nov; 346(1-2):288-92. PubMed ID: 25248955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Type 2 diabetes mellitus, brain atrophy, and cognitive decline.
    Moran C; Beare R; Wang W; Callisaya M; Srikanth V;
    Neurology; 2019 Feb; 92(8):e823-e830. PubMed ID: 30674592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural brain differences between monolingual and multilingual patients with mild cognitive impairment and Alzheimer disease: Evidence for cognitive reserve.
    Duncan HD; Nikelski J; Pilon R; Steffener J; Chertkow H; Phillips NA
    Neuropsychologia; 2018 Jan; 109():270-282. PubMed ID: 29287966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer's disease: a cross-sectional study of middle-aged adults from the broader New York City area.
    Mosconi L; Walters M; Sterling J; Quinn C; McHugh P; Andrews RE; Matthews DC; Ganzer C; Osorio RS; Isaacson RS; De Leon MJ; Convit A
    BMJ Open; 2018 Mar; 8(3):e019362. PubMed ID: 29574441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.